Loading
Cancer Related Gene Regulation · Journal article
Frontiers in Oncology · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This translational study identifies an ERα36–SLC7A5/LAT1 signaling axis in cervical cancer using integrated transcriptomic, immunofluorescence, and functional cell/animal models. The double-positive ERα36+/SLC7A5+ phenotype correlates with poor prognosis and altered BNCT sensitivity in preclinical systems, but clinical validation of prognostic or predictive utility is absent.
Mixed-methods translational study: integrated transcriptomic analysis, tissue microarray immunofluorescence, lentiviral knockdown/overexpression, in vitro functional assays, and xenograft models. Cervical cancer tissue samples (TCGA n=296, tissue microarray n=99); normal cervical tissue controls (GTEx n=10); SiHa cervical cancer cell line; female nude mice with cervical cancer xenografts. Intervention: ERα36 knockdown or overexpression via lentiviral transduction in SiHa cells; BNCT simulation in vitro and in vivo. Compared with: Control (wild-type or scrambled) cells; sham-treated xenografts. Not specified; TCGA is multi-institutional US/international consortium; GTEx is US-based.
SLC7A5 was significantly upregulated in cervical cancer tissues and correlated with M stage and poor prognosis ERα36+/SLC7A5+ double-positive phenotype was associated with shorter overall survival (P < 0.05) ERα36 knockdown suppressed proliferation, migration, and colony formation while promoting apoptosis in SiHa cells
ERα36 knockdown markedly attenuated BNCT-induced cytotoxicity in simulation experiments
Results suggest ERα36+/SLC7A5+ phenotype may stratify cervical cancer prognosis and predict BNCT response, but these claims require prospective clinical validation. BNCT sensitivity assessment is currently limited to preclinical simulation and animal models.
Translational study combining transcriptomic analysis, tissue immunofluorescence, and in vitro/in vivo cell models to characterize a signaling axis; lacks clinical trial evidence of BNCT response prediction or prognostic validation.
As stated by the source record.
Quoted from the source exactly as published.
Results suggest ERα36+/SLC7A5+ phenotype may stratify cervical cancer prognosis and predict BNCT response, but these claims require prospective clinical validation. BNCT sensitivity assessment is currently limited to preclinical simulation and animal models.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective To elucidate the role and molecular mechanism of the ERα36–SLC7A5/LAT1 signaling axis in the malignant progression of cervical cancer and its sensitivity to boron neutron capture therapy (BNCT). Methods Transcriptomic data from TCGA (n=296) and GTEx (n=10) were integrated to analyze SLC7A5 expression and its clinicopathological associations. Multiplex immunofluorescence staining was performed on a tissue microarray containing 99 cervical cancer specimens for spatial phenotyping. SiHa cell lines with stable ERα36 knockdown or overexpression were established using lentiviral transduction. CCK-8, flow cytometry, wound healing, Transwell, and colony formation assays were used to assess the effects of ERα36 on malignant phenotypes. Co-immunoprecipitation, Western blot, and qRT-PCR were employed to explore the interaction between ERα36 and LAT1 as well as downstream signaling changes. The impact of ERα36 on BNCT sensitivity was evaluated in both cellular and subcutaneous xenograft nude mouse models. Results SLC7A5 was significantly upregulated in cervical cancer tissues and correlated with M stage and poor prognosis. ERα36 and SLC7A5 exhibited robust spatial co-expression in the tumor microenvironment, and the double-positive phenotype was associated with shorter overall survival (P 0.05). ERα36 interacted with LAT1 and was associated with elevated CD98hc and EGFR expression. Knockdown of ERα36 suppressed proliferation, migration, and colony formation while promoting apoptosis; overexpression produced opposite effects. In BNCT simulation experiments, ERα36 knockdown markedly attenuated BNCT-induced cytotoxicity, as evidenced by increased colony formation, reduced apoptosis, and altered S-phase distribution. Both cellular and animal models consistently showed downregulation of ERα36 and LAT1 protein expression after BNCT. Conclusion The ERα36–SLC7A5/LAT1 axis associated with malignant phenotypes and BNCT sensitivity in cervical cancer. The ERα36+/SLC7A5+ spatial double-positive phenotype may represent a prognostic biomarker, and ERα36 may serve as a predictive marker for BNCT response.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.